Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-06-06 10:03 am Purchase | 2025-05-30 | 13G | Jade Biosciences, Inc. JBIO | FMR LLC | 4,735,951 14.700% | 4,735,951 (New Position) | Filing History |
| 2025-05-15 4:33 pm Purchase | 2025-04-28 | 13G | Jade Biosciences, Inc. JBIO | TCG Crossover GP I, LLC | 64,023 0.200% | 64,023 (New Position) | Filing History |
| 2025-05-05 4:26 pm Purchase | 2025-04-28 | 13G | Jade Biosciences, Inc. JBIO | Venrock Healthcare Capital Partners III, L.P. | 3,220,369 9.900% | 3,220,369 (New Position) | Filing History |
| 2025-05-05 09:43 am Purchase | 2025-04-28 | 13G | Jade Biosciences, Inc. JBIO | Frazier Life Sciences Public Fund, L.P. | 1,772,116 5.500% | 1,772,116 (New Position) | Filing History |
| 2025-05-01 6:31 pm Purchase | 2025-04-28 | 13D | Jade Biosciences, Inc. JBIO | Fairmount Funds Management LLC | 7,249,356 19.990% | 7,249,356 (New Position) | Filing History |
| 2025-04-30 4:51 pm Purchase | 2025-04-28 | 13D | Jade Biosciences, Inc. JBIO | RA CAPITAL MANAGEMENT L.P. | 1,324,954 4.100% | 1,324,954 (New Position) | Filing History |
| 2025-04-30 4:29 pm Purchase | 2025-04-28 | 13D | Jade Biosciences, Inc. JBIO | Atlas Venture Fund XII, L.P. | 51,406 0.200% | 51,406 (New Position) | Filing History |
| 2024-11-14 4:21 pm Sale | 2024-09-30 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 17,970 2.200% | -30,045 (-62.57%) | Filing History |
| 2024-06-20 6:00 pm Purchase | 2024-06-17 | 13D | Aerovate Therapeutics, Inc. AVTE | RA CAPITAL MANAGEMENT L.P. | 264,060 32.000% | 26,517 (+11.16%) | Filing History |
| 2024-04-30 4:16 pm Purchase | 2024-04-26 | 13D | Aerovate Therapeutics, Inc. AVTE | RA CAPITAL MANAGEMENT L.P. | 237,542 28.900% | 595 (+0.25%) | Filing History |
| 2024-02-20 7:09 pm Purchase | 2023-06-21 | 13D | Aerovate Therapeutics, Inc. AVTE | Sofinnova Venture Partners X L.P. | 108,780 13.800% | 677 (+0.63%) | Filing History |
| 2024-02-14 4:58 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 94 0.000% | -44,534 (-99.79%) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 48,015 6.100% | -8,467 (-14.99%) | Filing History |
| 2024-02-14 3:08 pm Sale | 2023-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management LP | 34,620 4.380% | -21,298 (-38.09%) | Filing History |
| 2024-02-09 4:28 pm Purchase | 2023-06-16 | 13G | Aerovate Therapeutics, Inc. AVTE | TCG Crossover GP I, LLC | 62,894 8.000% | 62,894 (New Position) | Filing History |
| 2023-06-27 5:00 pm Purchase | 2023-06-26 | 13D | Aerovate Therapeutics, Inc. AVTE | RA CAPITAL MANAGEMENT L.P. | 236,947 30.000% | 833 (+0.35%) | Filing History |
| 2023-02-14 4:00 pm Purchase | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Baker Bros. Advisors LP | 56,482 8.000% | 4,145 (+7.92%) | Filing History |
| 2023-02-14 3:10 pm Purchase | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Cormorant Asset Management LP | 55,918 7.950% | 3,613 (+6.91%) | Filing History |
| 2023-02-14 08:02 am Sale | 2022-12-31 | 13G | Aerovate Therapeutics, Inc. AVTE | Citadel Advisors LLC | 44,628 6.400% | -1,014 (-2.22%) | Filing History |
| 2023-02-03 7:24 pm Purchase | 2022-11-14 | 13D | Aerovate Therapeutics, Inc. AVTE | Sofinnova Venture Partners X L.P. | 108,104 15.400% | 673 (+0.63%) | Filing History |